OTCM
SCOLF
Market cap152mUSD
, Last price
USD
Name
Seed Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SEED Co.,Ltd. is an international manufacturer and supplier specializing in a broad spectrum of ophthalmic products. The company's extensive range includes various contact lenses, lens care solutions, fashionable spectacle frames, and other vision enhancement items, serving customers in Japan and across global markets. Their diverse contact lens collection features numerous daily disposable options, such as the SEED 1dayPure moisture, SEED Eye coffret 1day UV, SEED 1dayPure EDOF, SEED PlusMode 1day Homme, and JILL STUART 1day UV. They also offer specialized daily lenses, including multistage and astigmatism-correcting versions like the SEED 1dayPure moisture for astigmatism. Furthermore, SEED provides two-week disposable lenses through its SEED 2weekPure moisture series, which encompasses standard, multistage bifocal, and astigmatism-specific variants. Monthly replacement lenses, such as SEED MonthlyFine UV and monthly color lens UV, are also part of their portfolio, alongside advanced rigid gas permeable and medical contact lenses. In addition to vision correction products, SEED Co.,Ltd. designs and sells eyewear frames under well-known brands like Vivid Moon, ViVi fleurs, and Plusmix. The company also develops pharmaceutical products, including Adeno Test AD for the detection of adenovirus antigens, and other solutions aimed at improving visual health. Established in 1957, SEED Co.,Ltd. is based in Tokyo, Japan.
Key people
Tetsuya Sugiyama
Vice President, Chief Director of Administration, Representative Director · since 2025
Takeshi Fukuda
Managing Executive Officer, Chief Director of Production Technology, Director · since 2018
Jun Igarashi
Managing Executive Officer, Chief Director of Sales, Director · since 2023
Kikue Nakamura
Managing Executive Officer, Chief Director of Research & Development, Director of Academic Affairs, Director · since 2025
Nobutaka Shinjo
Managing Executive Officer, Chief Director of International Business, Director · since 2025
Katsuta Kanno
Executive Officer, Director in charge of Eye Care Sales in Main Sales unit · since 2025
Tomonori Akutsu
Executive Officer, Chief Director of Merchandise, Director of Logistics Management
Seiji Hashimoto
Executive Officer, Director in charge of Overseas Sales, General Manager of Subsidiary · since 2025
Takeshi Ishikawa
Executive Officer, Director of Business Planning · since 2024
Takashi Ito
Executive Officer, Director of Sales Capability Enhancement in Main Sales Unit · since 2024
Hiroko Kanazawa
Executive Officer, Director in charge of Main International Business Unit · since 2025
Masaki Kimura
Executive Officer, Deputy Chief Director of Production Technology · since 2025
Takeshi Kiriyama
Executive Officer, Chief Director of General Affairs, Director of General Affairs · since 2024
Kazuhiro Kobayashi
Executive Officer, Deputy Chief Director of Quality Assurance, Director of Quality Assurance · since 2025
Shin Kubota
Executive Officer, Deputy Chief Director of Production Technology, Director of Technology · since 2025
Toru Matsunaga
Executive Officer, Deputy Chief Director of Research and Development, Director of Development · since 2025
Takahiro Nakajima
Executive Officer, Director of Human Resources and Education in Main Administration Unit · since 2022
Takashi Saito
Executive Officer, Deputy Chief Director of International Business · since 2025
Sakae Yamaguchi
Executive Officer, Director of Corporate Communication · since 2025
Takao Sato
President, Director · since 2025
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||